Could a cheaper copy of ocrevus work just as well for MS?
NCT ID NCT06847724
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests whether CYB704, a proposed biosimilar to the MS drug Ocrevus, works the same way in the body. About 183 people with relapsing multiple sclerosis will receive either CYB704 or Ocrevus. Researchers will compare drug levels, MRI scans, and side effects to see if the biosimilar is a viable alternative.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ocrelizumab (proposed biosimilar CYB704)
What this could lead to
If successful, CYB704 could offer a more affordable treatment option for relapsing multiple sclerosis, potentially increasing access to care.
What could go wrong
This is a biosimilar study, not a new drug. Even if CYB704 matches Ocrevus in the body, long-term safety and effectiveness still need confirmation. As with Ocrevus, risks include infusion reactions and increased infection risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sandoz Investigational Site
Maitland, Florida, 32751, United States
-
Sandoz Investigational Site
Ormond Beach, Florida, 32174, United States
-
Sandoz Investigational Site
Banja Luka, Bosnia and Herzegovina
-
Sandoz Investigational Site
Bihać, Bosnia and Herzegovina
-
Sandoz Investigational Site
Sarajevo, Bosnia and Herzegovina
-
Sandoz Investigational Site
Pleven, Bulgaria
-
Sandoz Investigational Site
Plovdiv, Bulgaria
-
Sandoz Investigational Site
Sofia, Bulgaria
-
Sandoz Investigational Site
Varaždin, Croatia
-
Sandoz Investigational Site
Zagreb, Croatia
-
Sandoz Investigational Site
Rustavi, Georgia
-
Sandoz Investigational Site
Tbilisi, Georgia
-
Sandoz Investigational Site
Shtip, North Macedonia
-
Sandoz Investigational Site
Skopje, North Macedonia
-
Sandoz Investigational Site
Bydgoszcz, Poland
-
Sandoz Investigational Site
Katowice, Poland
-
Sandoz Investigational Site
Lodz, Poland
-
Sandoz Investigational Site
Lublin, Poland
-
Sandoz Investigational Site
Nowa Sól, Poland
-
Sandoz Investigational Site
Poznan, Poland
-
Sandoz Investigational Site
Szczecin, Poland
-
Sandoz Investigational Site
Warsaw, Poland
-
Sandoz Investigational Site
Zabrze, Poland
-
Sandoz Investigational Site
Belgrade, Serbia
-
Sandoz Investigational Site
Niš, Serbia
-
Sandoz Investigational Site 2
Sarajevo, Bosnia and Herzegovina
-
Sandoz Investigational Site 2
Plovdiv, Bulgaria
-
Sandoz Investigational Site 2
Sofia, Bulgaria
-
Sandoz Investigational Site 2
Tbilisi, Georgia
-
Sandoz Investigational Site 2
Katowice, Poland
-
Sandoz Investigational Site 2
Lublin, Poland
-
Sandoz Investigational Site 2
Poznan, Poland
-
Sandoz Investigational Site 3
Sofia, Bulgaria
-
Sandoz Investigational Site 3
Tbilisi, Georgia
-
Sandoz Investigational Site 4
Sofia, Bulgaria
-
Sandoz Investigational Site 4
Tbilisi, Georgia
-
Sandoz Investigational Site 5
Sofia, Bulgaria
-
Sandoz Investigational Site 5
Tbilisi, Georgia
-
Sandoz Investigational Site 6
Tbilisi, Georgia
-
Sandoz Investigational Site 7
Tbilisi, Georgia
-
Sandoz Investigational Site 8
Tbilisi, Georgia